JP2014516924A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516924A5
JP2014516924A5 JP2014504013A JP2014504013A JP2014516924A5 JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5 JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
less
citrate
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032462 external-priority patent/WO2012138958A1/en
Publication of JP2014516924A publication Critical patent/JP2014516924A/ja
Publication of JP2014516924A5 publication Critical patent/JP2014516924A5/ja
Pending legal-status Critical Current

Links

JP2014504013A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014516924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473121P 2011-04-07 2011-04-07
US61/473,121 2011-04-07
PCT/US2012/032462 WO2012138958A1 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014516924A JP2014516924A (ja) 2014-07-17
JP2014516924A5 true JP2014516924A5 (enExample) 2016-01-28

Family

ID=46969561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504013A Pending JP2014516924A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140023655A1 (enExample)
EP (2) EP2694100A4 (enExample)
JP (1) JP2014516924A (enExample)
KR (1) KR20140018966A (enExample)
CN (1) CN103596585A (enExample)
AU (2) AU2012240050B2 (enExample)
BR (1) BR112013025866A2 (enExample)
CA (1) CA2832556A1 (enExample)
EA (1) EA201391488A1 (enExample)
IL (1) IL228591A0 (enExample)
SG (1) SG193963A1 (enExample)
WO (1) WO2012138958A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3295957T1 (sl) * 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
WO2014169153A1 (en) * 2013-04-10 2014-10-16 Echogen, Inc. Peptide complexes and therapeutic uses
JP6179939B2 (ja) * 2013-07-09 2017-08-16 国立大学法人 筑波大学 高濃度γグロブリン製剤の粘度低下方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3256147B8 (en) * 2015-01-18 2020-10-21 Gloriana Therapeutics, Inc. Therapeutic protein formulations
CN116327922A (zh) * 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3134401A1 (en) 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
IL299671A (en) * 2020-07-13 2023-03-01 Merck Patent Gmbh Viscosity-reducing excipients and their combinations for high-concentration protein formulations
KR20230167968A (ko) * 2022-06-03 2023-12-12 주식회사 녹십자홀딩스 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
MXPA05004528A (es) * 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SI3295957T1 (sl) * 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
JP6078344B2 (ja) * 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
SG193964A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity

Similar Documents

Publication Publication Date Title
JP2014510152A5 (enExample)
KR102462041B1 (ko) 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
CN108883178B (zh) 含抗体制剂
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
JP2022087255A (ja) キャリア結合剤組成物およびそれを作製および使用する方法
JP2021059593A (ja) 担体および抗体からなる組成物およびその製造および使用方法
JP2019503349A5 (enExample)
RU2013155695A (ru) Препараты антител против с-мет
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
JP2018521135A5 (enExample)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
JP2014522843A5 (enExample)
NZ630020A (en) Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
JP2020537520A5 (enExample)
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
US20230203152A1 (en) Engineered anti-il-2 antibodies
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
JP2019506841A5 (enExample)
JP2013543505A5 (enExample)
RU2014143639A (ru) Регулируемые протеазой антитела